These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21251813)

  • 41. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
    Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
    Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
    Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
    Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
    Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
    Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docetaxel weekly with metastatic breast cancer.
    Twelves C
    Onkologie; 2007 Sep; 30(8-9):407-8. PubMed ID: 17848810
    [No Abstract]   [Full Text] [Related]  

  • 45. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
    Al-Batran SE; Hozaeel W; Tauchert FK; Hofheinz RD; Hinke A; Windemuth-Kieselbach C; Hübner A; Burmester M; Koenigsmann M; Wiegand J; Zur Hausen G; Linsse B; Kuhl R; Pauligk C
    Ann Oncol; 2015 Jun; 26(6):1244-1248. PubMed ID: 25755108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting the toxicity of weekly docetaxel in advanced cancer.
    Charles KA; Rivory LP; Stockler MR; Beale P; Beith J; Boyer M; Clarke SJ
    Clin Pharmacokinet; 2006; 45(6):611-22. PubMed ID: 16719542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study.
    Lee DW; Kang IH; Ismail F
    Med J Malaysia; 2020 Jul; 75(4):338-341. PubMed ID: 32723991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly docetaxel regimens and radiation pneumonitis.
    Mauri D; Tzachanis D; Tsekoura P; Xanthakis I; Tsali L; Roumbkou S; Fountzilas G
    J Support Oncol; 2008; 6(6):265-6. PubMed ID: 18724534
    [No Abstract]   [Full Text] [Related]  

  • 49. Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer.
    Chalvatzis N; Manthou ME; Tzamalis A; Hytiroglou P; Dimitrakos S
    Ocul Immunol Inflamm; 2014 Apr; 22(2):164-6. PubMed ID: 23876214
    [No Abstract]   [Full Text] [Related]  

  • 50. Weekly docetaxel in the treatment of metastatic breast cancer.
    Palmeri L; Vaglica M; Palmeri S
    Ther Clin Risk Manag; 2008 Oct; 4(5):1047-59. PubMed ID: 19209285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
    Leyssens B; Wildiers H; Lobelle JP; Gillis A; Paridaens R; Mombaerts I
    Ann Oncol; 2010 Feb; 21(2):419-423. PubMed ID: 19622592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer.
    Ishida S; Masuguchi K; Kawashiri T; Tsuji T; Watanabe H; Akiyoshi S; Kubo M; Masuda S; Egashira N
    Biol Pharm Bull; 2020; 43(4):663-668. PubMed ID: 32238707
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Not Available].
    Schieveen PG; Royer B;
    Therapie; 2010; 65(3):201-6. PubMed ID: 27392987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meibomian gland changes in breast cancer patients treated with docetaxel-partial results.
    Stoicescu EA; Cherecheanu AP
    Rom J Ophthalmol; 2023; 67(2):111-116. PubMed ID: 37522022
    [No Abstract]   [Full Text] [Related]  

  • 55. A systemic review of taxanes and their side effects in metastatic breast cancer.
    Lai JI; Chao TC; Liu CY; Huang CC; Tseng LM
    Front Oncol; 2022; 12():940239. PubMed ID: 36303832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    van Eijk M; Vermunt MAC; van Werkhoven E; Wilthagen EA; Huitema ADR; Beijnen JH
    BMC Cancer; 2022 Jan; 22(1):104. PubMed ID: 35078455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials.
    Vermunt M; Marchetti S; Beijnen J
    Clin Pharmacol; 2021; 13():21-32. PubMed ID: 33536797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report.
    Gluz O; Kolberg-Liedtke C; Marmé F; Thill M
    Geburtshilfe Frauenheilkd; 2020 Apr; 80(4):399-409. PubMed ID: 32322109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.
    Rivera E; Cianfrocca M
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):659-70. PubMed ID: 25596818
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.